StreetInsider.com News Articles

Form SCHEDULE 13G/A Protara Therapeutics, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919261.html

Form SCHEDULE 13G/A Protara Therapeutics, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919261.html

Form S-8 Protara Therapeutics,

Tue, 11 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26905954.html

Form S-8 Protara Therapeutics,

Tue, 11 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26905954.html

Protara Therapeutics, Inc. (TARA) Misses Q2 EPS by 2c

Tue, 11 Aug 2026 09:36:48 -0400

Protara Therapeutics, Inc. (NASDAQ: TARA) reported Q2 EPS of ($0.36), $0.02 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Protara Therapeutics, Inc. (TARA) click here.

Form 10-Q Protara Therapeutics, For: Jun 30

Tue, 11 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26901944.html

Form 10-Q Protara Therapeutics, For: Jun 30

Tue, 11 Aug 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26901944.html

Form 8-K Protara Therapeutics, For: Aug 11

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901911.html

Form 8-K Protara Therapeutics, For: Aug 11

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901911.html

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Tue, 11 Aug 2026 08:00:00 -0400

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026

The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures

Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027

On track to report interim results from THRIVE-3 registrational trial of IV

Form SCHEDULE 13G/A Protara Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC

Tue, 07 Jul 2026 18:43:00 -0400
si-local-file:///var/storage/secattach/20260707/26742972.html

Form SCHEDULE 13G/A Protara Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC

Tue, 07 Jul 2026 18:43:00 -0400
si-local-file:///var/storage/secattach/20260707/26742972.html

Form 4 Protara Therapeutics, For: Jun 29 Filed by: Shefferman Jesse

Wed, 01 Jul 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260701/26720725.html

Form 4 Protara Therapeutics, For: Jun 29 Filed by: Shefferman Jesse

Wed, 01 Jul 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260701/26720725.html